(AOF) – DMS announces a net profit group share of 3.9 million euros in the first half, “driven by the strategic refocusing of the group”, compared to a net loss of 4 million a year ago. The specialist in high-performance digital medical imaging posts an EBITDA of 1.9 million euros, or an EBITDA margin of 9.0%, compared to 7.7% in the first half of 2022. The group confirms its 2023 objective a turnover of 40 million euros, an expected growth of more than 12.5% (on a comparable basis), associated with an increase in profitability.
The group specifies that its two branches of activity contributed to growth in the first half, with an acceleration in bone densitometry.
The Radiology activity increased by 8% to 16.6 million euros and represented 80% of turnover (compared to 84% in the first half of 2022). The contract signed with Fujifilm Healthcare for the delivery of 96 RF (Radio/Fluoroscopy) radiology tables in Italy began as planned during the second quarter.
The Osteodensitometry activity increased by 46% to 4.2 million euros, now representing 20% of turnover (compared to 16% in the first half of 2022). The commercial dynamic continues, driven by export sales and the recovery of the Asian market post-pandemic. As a reminder, DMS Imaging is the third global player in the bone densitometry market, which constitutes a strong vector of growth for the group.
© 2023 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
